TRCT
MDCX

Tower Research Capital (TRC)’s Medicus Pharma MDCX Stock Holding History

Tower Research Capital (TRC)’s Portfolio MDCX Stock Details MDCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-121
Closed -$56 – 5754
2026
Q1 		$56 Buy
+121
New +$126 ﹤0.01% 5029

Other funds holding MDCX

ICP
Interchange Capital Partners Pittsburgh, Pennsylvania $532M AUM 26.57% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
MHC
May Hill Capital Cohasset, Massachusetts $479M AUM 31.88% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $120B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.48B AUM 24.77% 1-Year Est. Return

Tower Research Capital (TRC)'s MDCX Position: Q2 2026 in Review

Tower Research Capital (TRC) sold out of Medicus Pharma (MDCX) in Q2 2026, closing a stake of 121 shares — an estimated $56 sold.

Tower Research Capital (TRC) first reported a position in MDCX in Q1 2026 and held it in 1 quarter. The position peaked at $56 in Q1 2026. 23 funds tracked by Wall St. Rank hold MDCX as of Q2 2026.

  • Tower Research Capital (TRC) reported no remaining Medicus Pharma position as of Q2 2026 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 121 Medicus Pharma shares in Q2 2026, an estimated $56.
  • Tower Research Capital (TRC) first reported a position in Medicus Pharma in Q1 2026 and held it in 1 quarter.
  • Tower Research Capital (TRC)'s Medicus Pharma position peaked at $56 in Q1 2026.
  • 23 funds tracked by Wall St. Rank held Medicus Pharma as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.